Dimitry Nuyten
Chief Tech/Sci/R&D Officer bei ARCUS BIOSCIENCES, INC.
Vermögen: 2 Mio $ am 31.03.2024
Profil
Dimitry S.
A.
Nuyten is currently the Chief Medical Officer at Arcus Biosciences, Inc. He previously worked as the Group Medical Director at Bristol Myers Squibb Co. from 2008 to 2013, and as the Vice President at Pfizer Inc. from 2013 to 2019.
In 2021, he was the Chief Medical Officer & Senior Vice President at Nektar Therapeutics.
He also served as the Chief Medical Officer at Aduro BioTech, Inc. Dr. Nuyten holds a doctorate degree from both the University of Amsterdam and the University of Groningen.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ARCUS BIOSCIENCES, INC.
0,11% | 23.01.2024 | 99 195 ( 0,11% ) | 2 Mio $ | 31.03.2024 |
Aktive Positionen von Dimitry Nuyten
| Unternehmen | Position | Beginn |
|---|---|---|
| ARCUS BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 01.08.2022 |
Ehemalige bekannte Positionen von Dimitry Nuyten
| Unternehmen | Position | Ende |
|---|---|---|
| NEKTAR THERAPEUTICS | Chief Tech/Sci/R&D Officer | 01.04.2022 |
| PFIZER, INC. | Corporate Officer/Principal | 01.03.2019 |
| BRISTOL-MYERS SQUIBB COMPANY | Chief Tech/Sci/R&D Officer | 01.06.2013 |
| CHINOOK THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Dimitry Nuyten
| University of Amsterdam | Doctorate Degree |
| University of Groningen | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| PFIZER, INC. | Health Technology |
| NEKTAR THERAPEUTICS | Health Technology |
| ARCUS BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
